INTRODUCTION
The diagnosis of Treponema pallidum (Tp) infection is usually carried out by serologic methods. These include tests with nontreponemal antigen (rapid plasma reagin, RPR), whole bacteria-either purified (microhemagglutination assay, MHA-TP) or not (fluorescent treponemal antibody-absorption test, FTA-Abs)-and recombinant proteins. Laboratories mostly use the RPR and MHA-TP or FTA-ABS, or only the RPR (1) . The drawbacks of the RPR include the false positives and false negatives at the very early and late latent stages of the disease. Neither RPR nor MHA-TP (or FTA-Abs) tests can be automated, and they are sometimes difficult to interpret. Finally, the simultaneous or successive use of multiple tests improves diagnostic accuracy but increases health costs (2) (3) (4) .
ELISA tests that can be readily automated (BioELISA Syphilis, Captia Syphilis, Enzygnost Syphilis, and ICE Syphilis) have recently become available (5-9). They could reduce the laboratory work but their utility to detect the infection in its different stages must be demonstrated. Our aim was to determine the value of a single ELISA test (Enzygnost Syphilis, DadeBehring, Germany) to detect the maximum number of cases of this infection with adequate sensitivity and specificity, and to propose a protocol for the diagnosis of the infection that uses automated methods and the minimum number of nonautomated complementary tests.
MATERIAL AND METHODS Testing Protocol
A total of 821 serum were included in the evaluation, divided between several groups. Group 1 consisted of 40 sera from patients with primary infection with Tp, defined by the presence of chancre compatible with primary syphilis, RPR ≥ 16 (Macro-Vue RPR, Becton Dickinson Microbiology, Cockeysville, MD), MHA-TP at a titer ≥ 640 (Cellognost Syphilis, DadeBehring), FTA-Abs (+) (Trepo-Spot IF, Biomerieux, France), and age 35 ± 5 years old. Group 2 was comprised of 13 serologic recurrences, defined by a clinical history of syphilis and ≥ 4-fold increase in RPR titer between two samples and age 37 ± 5 years old. Group 3 was comprised of 348 sera from patients with asymptomatic latent infections, defined by a clinical history of syphilis and who are currently RPR-negative, MHA-TP with positivity at a titer of 80-160, and age 60 ± 10 years old. Of these, 136 were from patients with early latent syphilis (< 1 year of clinical evolution and FTA-Abs positive) and 212 from those with late latent syphilis (> 1 year clinical evolution and FTAAbs negative). Group 4 was comprised of five sera from individuals without syphilis and with anticardiolipin antibodies (autoimmune diseases, age 45 ± 6 years old). Group 5 was comprised of 15 sera from patients with arthritis due to Borrelia burgdorferi and with no clinical history of syphilis (age 30 ± 5 years old). All these patients had a history of a tickbite, articular disease in knee or elbow, and had IgG anti-B. burgdorferi in serum according to CDC interpretation criteria (10). Group 6 was comprised of 400 samples from blood donors and healthy pregnant women. Groups 4, 5, and 6 were used as negative control groups.
In all samples anti-Tp antibodies were determined by the ELISA test under study (Enzygnost Syphilis).
Serologic Methods
The RPR, MHA, and the FTA-ABS were performed according to the manufacturers' instructions (5). The ELISA was performed first with MegaFlex automated pipetting and then with the Behring ELISA Processor system (BEP III) (DadeBehring). Briefly, 25 µL of specimens from patients and controls (four negative and two positive controls) were transferred to microtiter wells. Enzygnost Syphilis is a competitive one-stage enzyme immunoassay with T. pallidum Nichols strain (inactivated) detergent extract antigen. Tp-specific antibodies (IgG and/or IgM) contained in the sample and the peroxidase-labeled antibodies (POD) (anti-Tp/POD conjugate) compete for binding to the Tp antigens coated onto wells of the microtitration plates. Unbound serum antibodies and conjugate antibodies are washed out and the enzyme activity of the bound conjugate is then determined. The enzyme component of the conjugate reacts with the working chromogen solution (tetramethylbenzidine (TMB) plus hydrogen peroxide), thereby producing a blue color. This reaction is terminated by the addition of stopping solution POD, resulting in a color change to yellow. The intensity of the resultant yellow color is inversely proportional to the concentration of Tp antibodies in the sample. The manufacturer recommends that samples with equivocal ELISA results be retested. However, no specimens tested in this study had equivocal results.
The chi-square test was used to assess the significance of the differences in performance criteria between the various tests.
RESULTS
The results are listed in Table 1 . We have obtained 100% positive results by Enzygnost in samples from groups 1 (primary infections), 2 (recurrences), and 3 (latent infections). We have not obtained any positive results (0%) by Enzygnost in samples from groups 4 (autoimmune diseases) and 6 (blood donors and healthy pregnant women). In samples from group 5 (Lyme borreliosis) we have obtained 13.3% positive results by Enzygnost. There were no samples with equivocal results in the present study. There was a good correlation between results obtained by Enzygnost and the status of patients to Tp in panels 1, 2, 3, 4, and 6. In panel 5, antibodies to Tp with Enzygnost were present in two (13.3%) acute infections with B. burgdorferi. Enzygnost was present in patients with late latent infection and negative FTA-ABS (P < 0.01). There were no cases of prozone phenomenon in our sample. The sensitivity, specificity, and positive and negative predictive values of Enzygnost for the diagnosis of past or recent primary Tp infection in the present series were 100, 99.5, 99.5, and 100%, respectively. This result was obtained when infected subjects were compared to noninfected subjects (Table 1) .
DISCUSSION
The definitive diagnosis of infection with Tp requires several laboratory tests. Different assays can be used depending on the stage of the infectious process, i.e., primary infection, reactivation, or chronic infection (3, 8) . Costs could be reduced if a smaller number of tests were used. The detection of anti-Tp antibodies requires the use of specific antigens with the greatest immunogenic power to reduce the number of false positives and negatives. The detection of syphilis in its tertiary stage and epidemiological studies of the infection are compromised when only nontreponemal tests are employed. The FTA-ABS and RPR tests can give false negative results after many years in patients with late latent infection. Finally, automated tests are desirable to save time and improve the reproducibility of results. The present study contributes our nine-year experience using a competitive ELISA test with purified whole antigen (Enzygnost Syphilis) for the diagnosis of infection with Tp at different stages. The high sensitivity and specificity of the EIA in the present study are similar to the findings in two previous studies that used EIA alone to diagnose syphilis, reporting sensitivities of 93.9 and 100% and specificities of 98.6 and 98.2% (6,7). Furthermore, in our series, the ELISA test was more sensitive than the FTA-ABS in the sera of subjects with late latent infection and as sensitive as MHA. Young et al. (9) had similar results using an ELISA test with recombinant antigens. It has been reported that recombinant antigens appear to be more specific than whole antigens, whether the latter are purified or not. Thus, assays with ICE Syphilis (Abbot), with three recombinant Tp antigens (TpN15, TpN17, TpN47) achieved better results than did those with Captia Syphilis (Centacor), which uses the native Tp antigen (9) . However, in the present study we only found false positives in patients with Lyme borreliosis.
In previous studies (1, 5, 7, 9) , some ELISA tests were assessed but without establishing infection diagnosis guide- (5) . Nevertheless, the false diagnoses produced in our study may suggest a need for further research on this issue, since infection with B. burgdorferi is relatively prevalent in some areas and may lead to a false diagnosis of infection with Tp.
In conclusion, the Enzygnost system is an efficacious method to detect Tp infection, with the caveat that false diagnoses may be produced. Because of this possibility, we propose the following additional tests when a positive result is obtained: (1) a nontreponemal test prior to antibiotic therapy as a baseline to monitor the clinical response; and (2) the FTA-ABS in the few cases where the patient's clinical history casts doubt upon a positive result by the Enzygnost Syphilis test.
